Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


Molecular MRI differentiation of VEGF receptor-2 levels in C6 and RG2 glioma models.

He T, Smith N, Saunders D, Pittman BP, Lerner M, Lightfoot S, Silasi-Mansat R, Lupu F, Towner RA.

Am J Nucl Med Mol Imaging. 2013 Jul 10;3(4):300-11. Print 2013.


In vivo detection of inducible nitric oxide synthase in rodent gliomas.

Towner RA, Smith N, Doblas S, Garteiser P, Watanabe Y, He T, Saunders D, Herlea O, Silasi-Mansat R, Lupu F.

Free Radic Biol Med. 2010 Mar 1;48(5):691-703. doi: 10.1016/j.freeradbiomed.2009.12.012. Epub 2009 Dec 23.


Combined molecular MRI and immuno-spin-trapping for in vivo detection of free radicals in orthotopic mouse GL261 gliomas.

Towner RA, Smith N, Saunders D, De Souza PC, Henry L, Lupu F, Silasi-Mansat R, Ehrenshaft M, Mason RP, Gomez-Mejiba SE, Ramirez DC.

Biochim Biophys Acta. 2013 Dec;1832(12):2153-61. doi: 10.1016/j.bbadis.2013.08.004. Epub 2013 Aug 17.


Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas.

He T, Smith N, Saunders D, Doblas S, Watanabe Y, Hoyle J, Silasi-Mansat R, Lupu F, Lerner M, Brackett DJ, Towner RA.

J Cell Mol Med. 2011 Apr;15(4):837-49. doi: 10.1111/j.1582-4934.2010.01091.x.


Molecular MRI of VEGFR-2 reveals intra-tumor and inter-tumor heterogeneity.

Chen F, Zhang Y, Cai W.

Am J Nucl Med Mol Imaging. 2013 Jul 10;3(4):312-6. Print 2013.


In vivo detection of c-Met expression in a rat C6 glioma model.

Towner RA, Smith N, Doblas S, Tesiram Y, Garteiser P, Saunders D, Cranford R, Silasi-Mansat R, Herlea O, Ivanciu L, Wu D, Lupu F.

J Cell Mol Med. 2008 Jan-Feb;12(1):174-86. doi: 10.1111/j.1582-4934.2008.00220.x. Epub 2007 Jan 9.


Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model.

Jun HY, Yin HH, Kim SH, Park SH, Kim HS, Yoon KH.

Korean J Radiol. 2010 Jul-Aug;11(4):449-56. doi: 10.3348/kjr.2010.11.4.449. Epub 2010 Jun 21.


Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma.

Ali MM, Janic B, Babajani-Feremi A, Varma NR, Iskander AS, Anagli J, Arbab AS.

PLoS One. 2010 Jan 15;5(1):e8727. doi: 10.1371/journal.pone.0008727.


"Facilitated" amino acid transport is upregulated in brain tumors.

Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, Blasberg R.

J Cereb Blood Flow Metab. 1998 May;18(5):500-9.


Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis.

Plate KH, Breier G, Millauer B, Ullrich A, Risau W.

Cancer Res. 1993 Dec 1;53(23):5822-7.


Vascular endothelial growth factor-driven glioma growth and vascularization in an orthotopic rat model monitored by magnetic resonance imaging.

Goldbrunner RH, Bendszus M, Sasaki M, Kraemer T, Plate KH, Roosen K, Tonn JC.

Neurosurgery. 2000 Oct;47(4):921-9; discussion 929-30.


Molecular magnetic resonance imaging approaches used to aid in the understanding of angiogenesis in vivo: implications for tissue engineering.

Towner RA, Smith N, Asano Y, He T, Doblas S, Saunders D, Silasi-Mansat R, Lupu F, Seeney CE.

Tissue Eng Part A. 2010 Feb;16(2):357-64. doi: 10.1089/ten.TEA.2009.0233.


Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study.

Valable S, Lemasson B, Farion R, Beaumont M, Segebarth C, Remy C, Barbier EL.

NMR Biomed. 2008 Nov;21(10):1043-56. doi: 10.1002/nbm.1278.


VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.

Patten SG, Adamcic U, Lacombe K, Minhas K, Skowronski K, Coomber BL.

BMC Cancer. 2010 Dec 15;10:683. doi: 10.1186/1471-2407-10-683.


BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.

Pochon S, Tardy I, Bussat P, Bettinger T, Brochot J, von Wronski M, Passantino L, Schneider M.

Invest Radiol. 2010 Feb;45(2):89-95. doi: 10.1097/RLI.0b013e3181c5927c.


PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.

Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC.

Neurosurgery. 2004 Aug;55(2):426-32; discussion 432.


Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors.

Sarin H, Kanevsky AS, Wu H, Sousa AA, Wilson CM, Aronova MA, Griffiths GL, Leapman RD, Vo HQ.

J Transl Med. 2009 Jun 23;7:51. doi: 10.1186/1479-5876-7-51.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk